Search Within

David A Knorr

Formats
  1. Journal Article (13)
  2. Meeting Abstract (6)
  3. Research Letter (2)
  4. Review (1)
Groups
  1. Department of Medicine (22)
  2. Hematologic Malignancies, Division of (22)
  3. Weinberg Fellows (22)
  4. Center for Hematologic Malignancies (11)
  5. GME, Medicine (9)
  6. Graduate Medical Education (9)

More Groups

People
  1. Jeffrey Wong (5)
  2. Lakshmi Ramanathan (4)
  3. Melissa Pessin-Minsley (4)
  4. Anthony Mato (3)
  5. Bernard Bochner (3)
  6. Christina Bravo (3)

More People

Years
  1. 2025 (2)
  2. 2024 (1)
  3. 2023 (2)
  4. 2022 (5)
  5. 2021 (7)
  6. 2020 (2)

More Years

Publications
  1. Blood (3)
  2. Blood Cancer Discovery (2)
  3. Journal of Clinical Oncology (2)
  4. Leukemia (2)
  5. Science Translational Medicine (2)
  6. Cancer Immunology Research (1)

More Publications

Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Hematology (3)
  3. Nature Publishing Group (3)
  4. American Association for the Advancement of Science (2)
  5. American Society of Clinical Oncology (2)
  6. Cell Press (2)

More Publishers

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade
    Journal Article

    Blanchard, L.; Vina, E.; Ljubetic, J.; Meneur, C.; Tarroux, D.; Baez, M.; Marino, A.; Ortega, N.; Knorr, D. A.; Ravetch, J. V.; more...
    Cell Reports Medicine (2025)

    Fulltext@MSK | Save
  • Correlative science from a phase I study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
    Meeting Abstract

    Bochner, B. H.; Alam, S. M.; Blanchard, L.; Yao, N.; Angulo-Lozano, J.; Wong, J.; Knorr, D.; Whiting, K.; Seshan, V.; Donahue, T.; more...
    Urologic Oncology: Seminars and Original Investigations (2025)

    Fulltext@MSK | Save
  • FcgRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment
    Journal Article

    Knorr, D. A.; Blanchard, L.; Leidner, R. S.; Jensen, S. M.; Meng, R.; Jones, A.; Ballesteros-Merino, C.; Bell, R. B.; Baez, M.; Marino, A.; more...
    Cancer Immunology Research (2024)

    Fulltext@MSK | Save
  • IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
    Journal Article

    Wong, J. L.; Smith, P.; Angulo-Lozano, J.; Ranti, D.; Bochner, B. H.; Sfakianos, J. P.; Horowitz, A.; Ravetch, J. V.; Knorr, D. A.
    Proceedings of the National Academy of Sciences of the United States of America (2023)

    Fulltext@MSK | Save
  • Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models
    Journal Article

    Parker, S.; McDowall, C.; Sanchez-Perez, L.; Osorio, C.; Duncker, P. C.; Briley, A.; Swartz, A. M.; Herndon, J. E. 2nd; Yu, Y. R. A.; McLendon, R. E.; more...
    Science Translational Medicine (2023)

    Fulltext@MSK | Save
  • Systematic evaluation of AML-associated antigens identifies novel anti-U5 snRNP200 therapeutic antibodies for the treatment of AML
    Meeting Abstract

    Knorr, K.; Erickson, C.; Wang, E.; Rahman, J.; Mi, X.; Lu, S.; Fox, N.; Penson, A.; Hogg, S.; Stanley, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy
    Meeting Abstract

    Wong, J. L.; Knorr, D.; Whiting, K.; Seshan, V. E.; Pietzak, E. J.; Donahue, T. F.; Cha, E. K.; Goh, A. C.; Smith, R.; Dalbagni, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG)
    Meeting Abstract

    Desjardins, A.; Chandramohan, V.; Landi, D. B.; Johnson, M. O.; Khasraw, M.; Peters, K. B.; Low, J.; Herndon, J. E.; Threatt, S.; Bullock, C. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
    Journal Article

    Herati, R. S.; Knorr, D. A.; Vella, L. A.; Silva, L. V.; Chilukuri, L.; Apostolidis, S. A.; Huang, A. C.; Muselman, A.; Manne, S.; Kuthuru, O.; more...
    Nature Immunology (2022)

    Fulltext@MSK | Save
  • Central diabetes insipidus induced by acute myeloid leukemia with DNMT3A mutation
    Journal Article

    Lakshmanan, P.; Asnani, H.; Knorr, D.
    Case Reports in Endocrinology (2022)

    Fulltext@MSK | Save